王雨辰，教授，博士生導師。國家海外高層次人才計畫入選者，安徽醫科大學高層次引進人才與青年後備人才，“東南學者”特聘教授。2010-2016年於中國科學技術大學獲細胞生物學博士學位，2016年至2025年在美國加利福尼亞大學洛杉磯分校(UCLA)從事博士後和助理研究員工作，曾獲得2024年度美國心臟學會(AHA)編委會最佳期刊論文獎, 和2023年度UCLA生命科學傑出獎提名等榮譽。
基本介紹
人物經歷,主要成就,研究論文,成果專利,所獲榮譽,
人物經歷
王雨辰2010年本科畢業於安徽大學，獲理學學士學位。2016年博士畢業於中國科學技術大學廉哲雄教授實驗室，獲細胞生物學博士學位。分別於2016-2020年和2020-2022年在美國加利福尼亞大學洛杉磯分校(UCLA)醫學院Lili Yang教授實驗室和Aldons J. Lusis教授實驗室進行博士後研究，2022-2025年在UCLA醫學院擔任Assitant Project Scientist工作，2025年7月加入安徽醫科大學基礎醫學院任獨立PI。
王雨辰開發基於巨噬細胞重編程調控區域微環境的免疫治療新策略，並且把免疫學研究與心臟病學的研究相結合，搭建並整合了單細胞多組學平台和系統遺傳學平台，建立心臟疾病研究的HMDP (Hybrid Mouse Diversity Panel)系統遺傳學平台，揭示複雜疾病中遺傳決定因素、環境因素、代謝產物和腸道菌群等對於器官微環境和心臟功能的影響，尤其是以腸源性調控因子為中心的“腸-心”軸對心力衰竭的調控作用，並通過細胞工程或者小分子藥物進行免疫干涉和強化治療。實驗室的主要研究方向為免疫微環境調控和心臟類疾病。
主要成就
研究論文
1. YCWang, YC Koay, C Pan, … Indole-3-Propionic Acid Protects against Heart Failure with Preserved Ejection Fraction. Circulation Research. Feb 16;134(4):371-389 (2024). IF=23.21.
2. YCWang, Y Cao, C Pan, … Heterogeneity of small intestinal immune and epithelial cells and their cellular response network to a western diet. Journal of Experimental Medicine. Mar 7; 220(5): 1-26 (2023). IF=17.58.
3. Y Cao, YCWang, Z Zhou, C Pan, Z Zhou, Y Meng, S Charugundla,…Liver-heart Crosstalk Mediated by Coagulation Factor XI (F11) Influences Heart Failure. Science. 22 Sep (2022). Vol 377, Issue 6613. IF=56.9
4. YCWang, X Wang, J Yu, F Ma, Z li … Targeting Monoamine Oxidase A-Regulated TAM Polarization for Cancer Immunotherapy. Nature Communications. June 10; 12, Article number: 3530 (2021). IF=17.69.
5. YCWang, HD Ma, XY Yin, YH Wang, QZ Liu, JB Yang, QH Shi, B Sun, ... ForkheadBox O1 Regulates Macrophage Polarization Following Staphylococcusaureus Infection: Experimental Murine Data and Review of the Literature. Clin Rev Allergy Immunol. Feb 29; 51 (3), 353-369 (2016). IF=11.3.
6. Y Li, Y Zhou, J Yu, YJ Kim, M Li, D Lee, K Zhou, Y Chen, Y Zhu, YC Wang,… Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitorcells using a clinically guided culture method. Nature Biotechnology. May 14, 43, pages329–344 (2024). IF=68.16.
7. E Zhu, J Yu, Y-R Li, F Ma, YC Wang, … Biomimetic cell stimulationwith a graphene oxide antigen-presenting platform for developing T cell-basedtherapies. Nature Nanotechnology. 19, pages1914–1922,September 23 (2024). IF=38.1.
8. Y Cao, C Pan, YC Wang, Z Zhou, V Jeian, Y Meng, G Campbell, …Identification of DNA Damage Repair Enzyme Ascc2 as Causal for Heart Failurewith Preserved Ejection Fraction (HFpEF). Circulation, April 4; Volume145, Number 14, (2022). IF=39.92.
9. Y Cao, L Vergnes, YC Wang, C Pan, KC Krishnan, TM Moore, Z Zhou, S Charugundla … Sex Differences in Heart Mitochondria: Relationship to Diastolic Dysfunction … Nature Communications. 04 July; 13, Article number:3850 (2022). IF=17.69.
10. X Wang, B Li, Yu Jeong Kim, YC Wang, Z Li, J Yu, … Targeting monoamineoxidase A for T cell-based cancer immunotherapy. Science Immunology. May 14;6(59): eabh2383. (2021). IF=30.63.
11. J Brown,Z Li, X Wang, YJ Kim, YC Wang, Y Zuo, W Hong, … Nanoformulationimproves antitumor efficacy of MAOI immune checkpoint blockade therapy withoutcausing aggression-related side effects, Frontiers in Pharmacology, 01 September (2022). IF=5.6.
12. J Cheng, M Cheng, S Sinha, I Cely, S Gladkikh, MT Han, G Zhang, Z Zhou, R Chuhg, IS Ahn, G Diamante, YC Wang, Z Wang, … Trimethylamine-N-Oxide AffectsCell Type–Specific Pathways and Networks in Mouse Aortato Promote Atherosclerotic Plaque Vulnerability, ATVB, Volume45, Number 10, 14 August (2025). IF=10.48.
13. Y-R Li, Z Li, Y Zhu, M Li, Y Chen, D Lee, CJ O, T Singh, G Dibernardo, W Guo,S Li, Y Zhou, Y Yu, A Kramer, M Wilson, K Zhou, ZS Dunn, Y Fang, J Yu, YJ Kim, J Huang, X Shen, YC Wang, R Hon, T Basso…Overcoming ovariancancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells, Med, 6(10):100804, 10 Oct (2025). IF=12.8.
14. Y-R Li, S Zeng; Z Dunn, Y Zhou, Z Li, J Yu, YC Wang, J Ku, … Off-the-shelf third-party HSC-engineered iNKT cells for ameliorating GvHD while preserving GvL effect in the treatmentof blood cancers., iScience. 25(9): 104859-104859.(2022). IF=5.08.
15. S Li, F Ma, T Yokota, G Garcia Jr., A Palermo, Y Wang, C Farrell, YC Wang, R Wu, Z Zhou, C Pan … Metabolic reprogramming and epigenetic changes of vitalorgans in SARS-CoV-2 induced systemic toxicity. JCI insight. Jan 25;6(2): e145027 (2021). IF=9.484.
16. Y-R Li, Y Zhou, Y Kim, Y Zhu, F Ma, J Yu, YC Wang, Chen X, Li Z, Zeng S, Wang X … Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy. Cell Rep. Med. Volume 2, Issue 11, Nov 16 (2021). IF=16.99.
17. Y Zhu, DJ Smith, Y Zhou, YR Li, J Yu, D Lee, YCWang, S Di Biase, ... Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer. CellStem Cell. Oct 3;25(4):542-557.e9. (2019). IF=24.63.
18. S DiBiase, X Ma, X Wang, J Yu, YC Wang,DJ Smith, Y Zhou, Z Li, YJ Kim, ... Creatine uptake regulates CD8 T cellantitumor immunity. Journal of Experimental Medicine. Dec2; 216 (12), 2869-2882 (2019). IF=17.58.
19. B Li, X Wang, IY Choi, YC Wang, S Liu, AT Pham, H Moon, DJ Smith, ... miR-146a modulates autoreactive Th17 celldifferentiation and regulates organ-specific autoimmunity. Journal of Clinical Investigation. Oct 2; 127 (10),3702-3716 (2017). IF=19.46.
成果專利
1. L Yang; X Wang; YC Wang; MONOAMINE OXIDASE BLOCKADE THERAPY FOR TREATING THROUGH REGULATING TUMOR ASSOCIATED MACROPHAGES (TAMS), US 2023/0391871 A1, 美國, EP 4232036 A4，歐洲.
所獲榮譽
2024年度美國心臟學會(American Heart Association, AHA)編委會年度最佳期刊論文獎
2023年度UCLA生命科學傑出獎提名
